Biblio
Oral decitabine plus cedazuridine and venetoclax in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: a single-centre, phase 1/2 study. Lancet Haematol. 2024.
Oral therapy for myelodysplastic syndromes/neoplasms and acute myeloid leukemia: a revolution in progress. Expert Rev Anticancer Ther. 2023:1-9.
. Raising the bar for lower-risk myelodysplastic syndromes. Leuk Lymphoma. 2023:1-10.
.